$0.54 0.0 2.7%
Last Trade - 9:00pm
| Market Cap | ÂŁ13.2m |
| Enterprise Value | ÂŁ1.60m |
| Revenue | ÂŁ375k |
| Position in Universe | 5472nd / 6431 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.38 | 0.17 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | May 17, 2000 |
| Public Since | October 27, 1993 |
| No. of Shareholders: | 12,200 |
| No. of Employees: | 29 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 33,442,945 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 997 Lenox Dr Ste 100, LAWRENCE TOWNSHIP, 08648-2317, United States |
| Web | http://celsion.com/ |
| Phone | +1 609 8969100 |
| Contact | Jeffrey Church (Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer) |
| Auditors | WithumSmith Brown PC |
As of 9:00pm, shares in Celsion are trading at $0.54, giving the company a market capitalisation of ÂŁ13.2m. This share price information is delayed by 15 minutes.
Shares in Celsion are currently trading at $0.54 and the price has moved by -60.17% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Celsion price has moved by -64.92% over the past year.
Of the analysts with advisory recommendations for Celsion, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Celsion is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Celsion is scheduled to issue upcoming financial results on the following dates:
Celsion does not currently pay a dividend.
Celsion does not currently pay a dividend.
Celsion does not currently pay a dividend.
To buy shares in Celsion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Celsion are currently trading at $0.54, giving the company a market capitalisation of ÂŁ13.2m.
Here are the trading details for Celsion:
Based on an overall assessment of its quality, value and momentum, Celsion is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Celsion are currently priced at $0.54. At that level they are trading at 1.04% discount to the analyst consensus target price of 0.00.
Analysts covering Celsion currently have a consensus Earnings Per Share (EPS) forecast of -0.633 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celsion. Over the past six months, the relative strength of its shares against the market has been -84.51%. At the current price of $0.54, shares in Celsion are trading at -62.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Celsion.
Celsion's management team is headed by:
Here are the top five shareholders of Celsion based on the size of their shareholding:
